Pfizer Announces 352nd Consecutive Dividend: Is the 6% Yield Sustainable?
Yahoo Finance ·
Pharmaceutical giant Pfizer recently announced a fourth-quarter dividend of $0.43 per share, marking its 352nd straight quarterly payout. This brings the forward annual dividend to $1.72, delivering an attractive yield of about 5.9%, which significantly outpaces the S&P 500 average of roughly 1%. However, income investors are questioning the safety of this payout as the company faces major patent cliffs. Key medications like Eliquis and Xeljanz lose U.S. patent exclusivity this year, with Ibrance and Xtandi following next year. To counter this, Pfizer is heavily investing in its oncology pipeline while relying on strong existing products like Nurtec, Lorbrena, and Padcev to maintain revenue. Notably, free cash flow surpassed $11 billion over the past four quarters, comfortably covering dividend obligations by over $1 billion. Management remains firmly committed to preserving and eventually growing the payout, helping push the stock up more than 17% year-to-date and outperforming the broader market.
AI 시장 분석
Pfizer declared a fourth-quarter dividend of $0.43 per share, extending its streak to 352 consecutive quarters and offering a high annual dividend yield of 5.9%. While this attractive figure is about six times the S&P 500 average dividend yield, concerns remain over pipeline gaps due to the patent expiration of major drugs. However, expectations for dividend stability are maintained, driven by the strong growth of new products like Nurtec and Lorbrena, and free cash flow exceeding $1.1 billion.
상승 영향
- Biotechnology — Pfizer maintains 352 consecutive quarters of dividends with a high dividend yield of 5.9%, while double-digit sales growth of key new products like Nurtec and $1.1 billion in free cash flow support dividend stability.
DYAX 전담 분석
Pfizer faces upcoming patent expirations for major blockbuster drugs such as Eliquis and Xeljanz, but it has proven its capacity to pay dividends by generating over $1.1 billion in free cash flow over the past four quarters. Year-to-date, the stock has risen over 17%, outperforming the S&P 500.
In the bullish scenario, the successful development of the oncology pipeline and the expansion of new drug sales will sustain stable cash flows, highlighting the appeal of high dividends. In the bearish scenario, if the revenue hit from patent expirations exceeds expectations, concerns over dividend cuts could trigger a stock decline and sell-off, necessitating close monitoring of free cash flow indicators.
AI가 생성한 분석으로 투자 자문이 아닙니다.
DYAX Investor Sentiment
Bullish (Long) 58% · Bearish (Short) 42%
426 participants
Related News
- Entegris, Micron, AMD, and Tech Peers Slide as Fed Focuses on Price Stability and Borrowing Costs Rise
- Sector Update: Energy Equities Climb in Late Friday Trading
- Sector Update: Tech Stocks Fall Late Afternoon
- Can Apple's Duo hype offset soft iPhone 18 demand?
- Warren Buffett's Berkshire Achieved 19.7% Annual Return Over 60 Years
- CoreWeave and Nebius Slide as Wall Street Faces AI Financing Concerns and Rising Fear
